bronchiectasis
BRONCHIECTASIS
Bronchiectasis is an irreversible pathologic dilatation or ectasia of the bronchi due to repeated airway infection and inflammation.
It enhances susceptibility to bronchial infection and increases inflammatory reaction which causes further lung damage.
Classic symptoms of of bronchiectasis are cough with chronic sputum production along with recurring infective exacerbations and hemoptysis.

Specific Therapy for Individual Causes

Hypogammaglobulinemia
  • Administer IV immunoglobulins w/ guidance & supervision from an immunologist
Primary Ciliary Dyskinesia
  • More intensive therapy based on the assumption that disease progression is more likely
  • Emphasis on physical therapy
TB, HIV, Rheumatoid Arthritis, Sarcoidosis, GERD, Chronic Rhinosinusitis
  • Treat active associated disease based on existing guidelines
  • Bronchiectasis may precede, accompany or follow the development of associated disease
Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Control of asthma & prevention of damage from acute exacerbations of ABPA
  • Consider maintenance oral corticosteroids
  • Antifungal therapy (eg Itraconazole) remains 2nd-line choice, unless there is associated invasive aspergillosis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 30 Apr 2019
A shorter regimen comprising a seven-drug cocktail which included high-dose moxifloxacin for 9 months was noninferior to the WHO*-recommended long regimen of 20 months for treating rifampicin-resistant tuberculosis (TB), according to the STREAM** study, providing a feasible and lower-cost treatment option in resource-poor setting.
31 Jan 2017
New drug applications approved by US FDA as of 16 - 31 January 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.